Nora Therapeutics to Present at 26th Annual ROTH Conference

PALO ALTO, Calif., March 4, 2014 /PRNewswire/ -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to present at the 26^th Annual ROTH Conference at the Ritz-Carlton in Laguna Niguel, CA, on Monday, March 10, 2014 at 4:15 p.m. PDT.

About Nora Therapeutics, Inc.
Nora Therapeutics is a privately-held biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss, two reproductive conditions with significant unmet need. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information, please visit our website at www.noratherapeutics.com.

SOURCE Nora Therapeutics